Home LiteratureArticle Details
PMID: 12511172 Published · ppublish English Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations.

Archives of general psychiatry ·Vol. 60 ·No. 1 ·2003-01-00 ·Pages 49-56

Hoffman RE, Hawkins KA, Gueorguieva R, Boutros NN, Rachid F, Carroll K, Krystal JH

Abstract

Neuroimaging studies suggest that auditory hallucinations (AHs) of speech arise, at least in part, from activation of brain areas underlying speech perception. One-hertz repetitive transcranial magnetic stimulation (rTMS) produces sustained reductions in cortical activation. Recent results of 4-day administration of 1-Hz rTMS to left temporoparietal cortex were superior to those of sham stimulation in reducing AHs. We sought to determine if a more extended trial of rTMS could significantly reduce AHs that were resistant to antipsychotic medication. Twenty-four patients with schizophrenia or schizoaffective disorder and medication-resistant AHs were randomly allocated to receive rTMS or sham stimulation for 9 days at 90% of motor threshold. Patients receiving sham stimulation were subsequently offered an open-label trial of rTMS. Neuropsychological assessments were administered at baseline and during and following each arm of the trial. Auditory hallucinations were robustly improved with rTMS relative to sham stimulation. Frequency and attentional salience were the 2 aspects of hallucinatory experience that showed greatest improvement. Duration of putative treatment effects ranged widely, with 52% of patients maintaining improvement for at least 15 weeks. Repetitive transcranial magnetic stimulation was well tolerated, without evidence of neuropsychological impairment. These data suggest that the mechanism of AHs involves activation of the left temporoparietal cortex. One-hertz rTMS deserves additional study as a possible treatment for this syndrome.

MeSH Terms
Adult Antipsychotic Agents/therapeutic use Drug Resistance Female Functional Laterality/physiology Hallucinations/diagnosis,drug therapy,therapy Humans Male Neuropsychological Tests Parietal Lobe/physiology Psychotic Disorders/drug therapy,therapy Schizophrenia/diagnosis,drug therapy,therapy Schizophrenic Psychology Temporal Lobe/physiology Transcranial Magnetic Stimulation/therapeutic use Treatment Outcome
Chemicals
Antipsychotic Agents
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Hoffman Ralph E
Department of Psychiatry, Yale University School of Medicine, Yale-New Haven Psychiatric Hospital, 20 York St LV108, New Haven, CT 06504, USA. ralph.hoffman@yale.edu
Hawkins Keith A
Gueorguieva Ralitza
Boutros Nash N
Rachid Fady
Carroll Kathleen
Krystal John H
Article Info
Journal
Archives of general psychiatry
Abbr.
Arch Gen Psychiatry
ISSN
0003-990X
Published
2003-01-00
Pages
49-56
Language
English
Region
United States
NLM ID
0372435
Subset
IM
Grants
NIMH NIH HHS · R21 MH063326-02 · United States
NIMH NIH HHS · R21 MH063326 · United States
NIDA NIH HHS · P50 DA009241 · United States
NIMH NIH HHS · R21 MH063326-01 · United States
NCRR NIH HHS · RR00125 · United States
NIAAA NIH HHS · KO2AA00261-01 · United States
NIMH NIH HHS · R21MH63326 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com